SOPHiA GENETICS SA (SOPH)
Automate Your Wheel Strategy on SOPH
With Tiblio's Option Bot, you can configure your own wheel strategy including SOPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SOPH
- Rev/Share 1.0049
- Book/Share 1.2808
- PB 2.4594
- Debt/Equity 0.3519
- CurrentRatio 3.1112
- ROIC -0.5439
- MktCap 210517965.0
- FreeCF/Share -0.6829
- PFCF -4.6118
- PE -3.1819
- Debt/Assets 0.2054
- DivYield 0
- ROE -0.6347
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SOPH | Craig Hallum | -- | Buy | -- | $11 | Dec. 18, 2024 |
News
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago.
Read More
SOPHiA GENETICS Reports First Quarter 2025 Results
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON and ROLLE, Switzerland , May 6, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Revenue was $17.8 million, up 13% year-over-year or 15% on a constant currency basis Gross margin was 68.7% on a reported basis and 75.7% on an adjusted basis, up from 65.9% and 70.5% in the prior year period, respectively IFRS net loss increased 27% year-over-year to $17.4 million (including a net foreign exchange P&L impact of $5.2 million), and adjusted …
Read More
SOPHiA GENETICS Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
Published: April 28, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON and ROLLE, Switzerland , April 28, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and global leader in data-driven medicine, today announced the expansion of its ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to accelerate the deployment of MSK-ACCESS® powered with SOPHiA DDM™ globally. Building on the initial collaboration announced in October 2024 , this new phase will extend the test's reach to a total of 30 clinical institutions worldwide in 2025.
Read More
SOPHiA GENETICS to Announce Financial Results for First Quarter 2025 on May 6, 2025
Published: April 22, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON and ROLLE, Switzerland , April 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter 2025 before U.S. markets open on Tuesday, May 6, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.
Read More
SOPHiA GENETICS (SOPH) Upgraded to Buy: What Does It Mean for the Stock?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
SOPHiA GENETICS (SOPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Read More
About SOPHiA GENETICS SA (SOPH)
- IPO Date 2021-07-23
- Website https://www.sophiagenetics.com
- Industry Medical - Healthcare Information Services
- CEO Dr. Jurgi Camblong M.B.A., Ph.D.
- Employees 423